Glaxosmithkline (GSK) Stock
Global healthcare company focused on pharmaceuticals and vaccines. Here's the price, business snapshot, and what's worth knowing about Glaxosmithkline in June 2026.
GlaxoSmithKline PLC (GSK), listed as a sponsored ADR in the US under ticker GSK, is a large, diversified global healthcare company with a market capitalisation of roughly $89 billion. The business focuses on pharmaceuticals and vaccines after spinning off much of its consumer healthcare arm (Haleon) in recent years. Key investor considerations include R&D pipeline progress—particularly in respiratory, HIV and immunology areas—vaccine performance, regulatory approvals and patent expiries. GSK has a history of paying dividends, which may appeal to income-oriented investors, but dividend levels and the share price can fluctuate. Corporate strategy, partnerships and potential M&A are common catalysts. Risks include clinical trial setbacks, pricing and competition, currency and geopolitical exposure, and regulatory scrutiny. This summary is general educational information and not personal financial advice; investing involves risk, values can rise or fall, and past performance is not a reliable indicator. Consult a financial adviser for suitability.
Why It’s Moving
GSK pressure builds as analysts flag execution risk and limited upside after a tough stretch.
- Berenberg cut GSK to Hold, signaling that investors may need clearer evidence from upcoming product launches before the stock can re-rate higher.
- J.P. Morgan kept a Sell view, citing weak vaccine performance and expectations for declining EPS, which suggests earnings power could remain under pressure.
- Market commentary points to limited upside in analyst models, reinforcing the view that the shares may be vulnerable if execution on new medicines or commercial growth disappoints.
GSK pressure builds as analysts flag execution risk and limited upside after a tough stretch.
- Berenberg cut GSK to Hold, signaling that investors may need clearer evidence from upcoming product launches before the stock can re-rate higher.
- J.P. Morgan kept a Sell view, citing weak vaccine performance and expectations for declining EPS, which suggests earnings power could remain under pressure.
- Market commentary points to limited upside in analyst models, reinforcing the view that the shares may be vulnerable if execution on new medicines or commercial growth disappoints.
When is the next earnings date for GlaxoSmithKline (GSK)?
The next earnings date for GSK is expected on July 28, 2026, with some sources showing July 29, 2026 as the estimated release date. The report will cover Q2 2026. This timing is consistent with GSK’s historical late-July earnings pattern.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding GlaxoSmithKline's stock, with a target price indicating potential decline.
Financial Health
GlaxoSmithKline is performing well, with strong revenue, cash flow, and profit margins.
Dividend
GlaxoSmithKline's projected dividend yield of 4.1% is decent for investors seeking dividend income. If you invested $1000 you would be paid $41 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring GSK
AI-Driven Pharma Stocks | Pipeline Innovation
Novo Nordisk's partnership with OpenAI highlights a massive shift as major drugmakers integrate generative AI into their core operations. This basket captures the pharmaceutical giants optimizing their pipelines alongside the tech titans providing the underlying AI infrastructure.
Published: 15 April 2026
Explore BasketPharma Manufacturing | What's Next After TrumpRx
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
Published: 14 March 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketUK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Published: 2 December 2025
Explore BasketEU Stocks: Could Ras Al Khaimah Investors Diversify?
As the UAE diversifies its economy beyond local markets, residents in Ras Al Khaimah may look to international opportunities for their own portfolios. This basket offers exposure to a collection of leading European blue-chip companies listed on major EU and US exchanges.
Published: 26 November 2025
Explore BasketSanofi Dupixent Success Overview | Pharma Investment
Sanofi's recent profit surge, driven by its blockbuster drug Dupixent, highlights a powerful investment theme. This idea focuses on innovative pharmaceutical companies with high-growth drugs and the broader ecosystem that supports their success.
Published: 24 October 2025
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketInjectable Drug Revolution: What's Next Beyond Pills?
The UK's approval of GSK's long-acting HIV drug marks a pivotal shift from daily pills to less frequent injections. This theme focuses on the pharmaceutical innovators leading the charge in developing and commercializing long-acting therapeutic technologies.
Published: 17 October 2025
Explore BasketHealthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: 14 October 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: 23 September 2025
Explore BasketJohnson & Johnson (Healthcare Diversification)
As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.
Published: 16 September 2025
Explore BasketPharma Investment Basket Explained (Eli Lilly+)
Nigeria's growing population is increasingly seeking exposure to global health advancements, particularly from leading pharmaceutical innovators. This basket provides potential exposure to this trend through a collection of US and EU-listed pharmaceutical, biotechnology, and healthcare supply chain companies.
Published: 11 September 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: 10 September 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: 5 August 2025
Explore BasketDefensive Plays For A Slowing Economy
U.S. job growth has slowed more than expected, signaling that economic uncertainty from trade tensions is impacting the labor market. This creates a potential investment opportunity in companies that are resilient to economic headwinds, such as those in defensive sectors and essential business services.
Published: 4 August 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: 3 August 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: 1 August 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: 15 July 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: 3 July 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: 2 July 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: 1 July 2025
Explore BasketBoomer Stocks
Discover a collection of iconic, industry-leading companies with deep market roots and reliable dividend histories. These household names have been carefully selected by our analysts for their strong brands, steady cash flow, and potential for long-term stability.
Published: 17 June 2025
Explore BasketMade in the UK
Diversify your portfolio with some of Britain's most established companies. Our analysts have carefully selected these UK powerhouses that span multiple industries from banking to pharmaceuticals, energy to consumer goods.
Published: 10 May 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: 6 May 2025
Explore BasketUK-US Trade Deal
These carefully selected UK stocks could benefit from the newly announced US-UK trade agreement, the first under Trump's second administration. Our professional analysts have identified companies with potential upside as tariffs are cut on British exports like steel, aluminum, and more.
Published: 3 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Late-stage trials and approvals can change growth prospects, though clinical setbacks are possible and can affect share value.
Vaccines & R&D
A strong vaccines franchise supports revenue potential, but R&D outcomes are uncertain and require close monitoring.
Global Reach & Risks
Exposure to international markets diversifies sales but brings currency, regulatory and geopolitical risks that can impact performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
